Takemoto Hiroyoshi, Nishimura Junichi, Komori Takamichi, Kim Ho Min, Ota Hirofumi, Suzuki Rei, Ikenaga Masakazu, Ikeda Masataka, Yamamoto Hirofumi, Satoh Taroh, Hata Taishi, Takemasa Ichiro, Mizushima Tsunekazu, Doki Yuichirou, Mori Masaki
Department of Surgery, Kinki Central Hospital, Kurumaduka 3-1, Itami, Hyogo, Japan.
Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, Japan.
Int J Clin Oncol. 2017 Feb;22(1):88-95. doi: 10.1007/s10147-016-1022-9. Epub 2016 Jul 27.
We previously reported in the SENRI trial on the usefulness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer patients receiving an oxaliplatin-based regimen which is classified as moderately emetogenic cancer chemotherapy. In the present subgroup analysis of the SENRI trial, we assessed the risk factors for CINV in colorectal cancer patients who received oxaliplatin-based chemotherapy.
Multivariate logistic regression models were used to assess the impact of aprepitant use and patient characteristics on vomiting and nausea. We also assessed the proportion of CINV in patients by gender.
Female gender and aprepitant use were associated with the incidence of vomiting and no significant nausea. Significantly more men achieved no vomiting than women (92.9 vs 84.5 % in men and women, respectively; P = 0.0001). The rate of no nausea, complete response, complete protection, and total control was also higher in men. The rate rescue therapy use was significantly higher in women than men. We compared the rate of CINV between aprepitant and control groups and found a significant difference in male patients who achieved no vomiting and complete protection in the overall phase. In women, the rate of no nausea, no vomiting, and total control was higher in the aprepitant group than in the control group.
Gender and aprepitant use were risk factors for CINV in colorectal patients who received oxaliplatin-based chemotherapy. Aprepitant therapy was more effective for women than for men in the prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen.
我们之前在SENRI试验中报告了阿瑞匹坦对接受基于奥沙利铂方案的结直肠癌患者预防化疗引起的恶心和呕吐（CINV）的有效性，该方案被归类为中度致吐性癌症化疗。在SENRI试验的本次亚组分析中，我们评估了接受基于奥沙利铂化疗的结直肠癌患者发生CINV的危险因素。
使用多因素逻辑回归模型评估阿瑞匹坦的使用和患者特征对呕吐和恶心的影响。我们还按性别评估了患者中CINV的比例。
女性和使用阿瑞匹坦与呕吐发生率相关，且无明显恶心。男性无呕吐的比例显著高于女性（男性和女性分别为92.9%和84.5%；P = 0.0001）。男性无恶心、完全缓解、完全预防和总体控制的比例也更高。女性使用挽救治疗的比例显著高于男性。我们比较了阿瑞匹坦组和对照组之间CINV的发生率，发现在总体阶段无呕吐和完全预防的男性患者中存在显著差异。在女性中，阿瑞匹坦组无恶心、无呕吐和总体控制的比例高于对照组。
性别和阿瑞匹坦的使用是接受基于奥沙利铂化疗的结直肠癌患者发生CINV的危险因素。在接受基于奥沙利铂方案的结直肠癌患者中，阿瑞匹坦治疗对女性预防CINV比男性更有效。
